Sign in

    William McFarland

    Senior Analyst at GDR Research

    William McFarland is a Senior Analyst at GDR Research, specializing in equity research and in-depth company analysis within the technology and consumer sectors. He actively covers companies such as Apple, Microsoft, Alphabet, and Tesla, with a track record that includes a documented TipRanks success rate of 61% and an average annualized return of 12.3% on stock recommendations. McFarland started his career as a research associate at Morgan Stanley in 2014, progressed to analyst roles at Jefferies and Piper Sandler, and joined GDR Research in 2021, where he has since been recognized for his insightful market outlooks and data-driven reports. He is registered with FINRA, holding both Series 7 and Series 63 licenses, and is known for his actionable calls and appearances in industry rankings.

    William McFarland's questions to MARIMED (MRMD) leadership

    William McFarland's questions to MARIMED (MRMD) leadership • Q2 2024

    Question

    William McFarland from GDR Research requested additional commentary on the reasons behind the significant disconnect between MariMed's stock price and its reported financial progress.

    Answer

    CEO Jon Levine expressed strong frustration, describing himself as 'angry' about the market's inefficiency in valuing cannabis stocks. He cited the recent Verano deal as a clear example where a peer sold a fraction of its assets for more than its entire market capitalization, highlighting a sector-wide undervaluation that affects MariMed despite its strong balance sheet, revenue growth, and positive cash flow.

    Ask Fintool Equity Research AI